When was Osel founded?

Osel was founded in 2001 and raised its 1st funding round 8 years after it was founded.

Where is Osel located?

Osel is headquartered in Mountain View, United States.

How many employees does Osel have?

As of Jul 31, 2026, the latest employee count at Osel is 14.

Is Osel a funded company?

Osel is a funded company, having raised an undisclosed amount across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 11, 2009.

When was the latest funding round of Osel?

Osel's latest funding was a $***** Grant (prize money) round on May 20, 2025, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.98B in funding in 2026 to date.

Where does Osel rank among its competitors?

Osel ranks 203rd amongst 612 active competitors, of which 216 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sirnaomics, which secured $17.7M in Sep, 2025.

Who are the top competitors of Osel?

Osel's top competitors include Alnylam, Novozymes and Spark Therapeutics. Among them, Sirnaomics secured the most recent funding round in September, 2025.

Osel - 2026 Company Profile, Funding & Competitors

Company Details

Provider of microbiotics for women's health and GI diseases. Its proprietary approach leverages the differences between healthy and diseased microbiomes to develop new microbial drugs. Its lead candidate is a Lactobacillus strain that is in phase II trials for recurrent bacterial vaginosis and recurrent urinary tract infections. In addition, the company has a strain of Clostridium butyricum in phase II trials to treat antibiotic-associated diarrhea and in preclinical testing for inflammatory bowel disease, and it is also investigating a possible application for HIV infections.

Key Metrics

Founded Year

2001

Location

Mountain View, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), May 20, 2025, $*****

Investors

HHS

Ranked

203^rd among 612 active competitors

Employee Count

14 as on Jul 31, 2026

Similar Companies

Alnylam & 766 more

View Osel's full profile

Osel has raised funding over 9 rounds. Its first funding round was on Mar 11, 2009. Its latest funding round was a Grant (prize money) round on May 20, 2025 for $*****. 1 investor participated in its latest round. Osel has 1 institutional investor.

Here is the list of recent funding rounds of Osel:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 20, 2025	7917586	Grant (prize money)	1190841	4185693	1836335	8722905
Aug 01, 2020	9955387	Grant (prize money)	8087687	5419568	8173352	HHS
Apr 01, 2016	3434411	Grant (prize money)	1611018	4173661	3868986	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Osel's funding rounds and investors

Osel's employee count trend

Osel has 14 employees as of Jul 26. Here is Osel's employee count trend over the years:

Uncover Osel's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Osel include Alnylam, Novozymes and Spark Therapeutics. Here is the list of Top 10 competitors of Osel, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, CHV & 3 others	73/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
8th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	69/100
10th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
203rd	Osel 2001, Mountain View (United States), Funding Raised	Provider of microbiotics for women's health and GI diseases	-	HHS	42/100